Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Those Risk Factor statements are required by law. Go look at any other company S1 or even a 10-Q/K and those statements are there.
Welcome to drug development… it’s a long risky road. To be honest, this whole thing requires Metformin Eye drop to achieve and successful IND filing and initiating a clinical trial
IMO it’s pursuing Metformin Eye Drop 1st
Total cost estimates are $30 million to achieve inflection points, I think Metformin eye drop will be leverage to achieve their goals
USE OF PROCEEDS
We estimate that the net proceeds from this offering, after deducting underwriting discounts and offering expenses payable by us, will be approximately $7.0 million. If the underwriter’s over-allotment option is exercised in full, we estimate that our net proceeds will be approximately $7.8 million.
Rabies
We estimate that it will cost approximately $6.1 million to get through a combined phase I / II clinical trial. Of this amount, we will first need to spend approximately $2.3 million in costs related to pre-clinical trials, IND-enabling studies, manufacturing, and other costs related to submitting IND applications. Provided we are able to receive IND approval, we estimate that it will cost approximately an additional $3.8 million to conduct and complete a combined phase I / II clinical trial.
Glioblastoma
We estimate that it will cost approximately $4.4 million in pre-clinical, IND-enabling studies, manufacturing, and other costs related to submitting an IND application
Retinal Degeneration
We estimate that it will cost approximately $2.0 million in pre-clinical, IND-enabling studies, manufacturing, and other costs related to submitting an IND application. Provided we are able to receive IND approval, we estimate that it will cost approximately an additional $1.0 million to conduct and complete a phase 1 clinical trial of dry age-related macular degeneration (AMD) and Geographic Atrophy. Pursuant to the CRADA (see section of this Prospectus entitled “Product Development” – Degenerative Eye Diseases” for more information), our contribution to the first clinical trial will be a maximum of $115,000, with the balance to be covered by the National Eye Institute.
COVID-19
We estimate that it will cost approximately $18 million in pre-clinical, IND-enabling studies, manufacturing, and other costs related to submitting an IND application.
Scroll to bottom , several signatures signed the S1A
September is here. Looking like a proposed > $7 million offering down from $10 million
Lockup agreements remain in effect for 180 days post Uplist.
Revenue?
Ask Hans can we get a glimpse of revenue. Or what is his revenue projections for End of Year? We need to see money flow
Surprisingly for drug development CUBT is moving pretty steady.
0.20 stock ; swing traders will begin to reload around here.
Attorney Letter filed!
https://www.otcmarkets.com/financialReportViewer?id=333337
Really interested in “Payment Processing” service from Smart Brand Digital. Big reason to support SAFE Act. That’s key.
Great! Q1 out if the way!
Next we need a PR for shareholders outlook and summary. Or a shareholder call and Q&A. Time to be transparent on the future outlook.
Add/Hold
Remember this. Hans flew to meet with Board of Director’s and their new appointments. He came back a bit different and he stated he was instructed by the BoD to lay low.
It looks like the BoD is providing wise counsel to lay off tweets and execute required steps to ensure Verdosa Holdings starts off correctly and not half ass.
The BoD members are heavyweights and I believe if they didn’t have a future with Verdosa they have the means (money/lawyers) to get their profile removed.
But all BoD images and name remain on website!
Excellent update. I’ve been waiting for this step. FDA IND filing on the horizon!
What’s needed is:
1. Successful filing of 10-Q May 16th. Need revenue accurately reflected.
2. Formal shareholders update by PR or open call
Anyone calculate their own SP projections.
I have us at $0.02
Awesome! Filings complete.
Verdosa Holdings set..this was the required step to get the financials and acquisitions squared away before the transition to Verdosa Holdings… Hans is here to stay. Next couple years looking good.
S1A is loaded with information.
Bharti highlights Metformin in interview below.
I did the same weeks ago. Message Tony Gallo on Sapphire risk. He also said contact Hans. So he did not deny… this is in play.
Will we get a positive surprise “soon”?
Chart is mildly improving. Adding this coming week.
If a crime was committed then the gov would have made allegations or shut this down immediately.
Have fun everyone, trade to win. Anyone involved in MEDH is here for money making potential. Most don't even consume cannabis. lol
But would like to see the Lazy Daze patrons buy some shares.
One does not strike a deal with the United States Government without several meetings, negotiations, plans and future benefit of a mutual agreement.
Theses deals are vetted by committees, lawyers, and regulatory agencies.
hans@verdosaholdings.com
Hans new email. Good luck everyone!
OS increased from 216 mil to 220 mil.
https://www.otcmarkets.com/stock/MITI/security
OTC …. Love it.
And this is why they have NYSE/NASDAQ.
We are in the trenches here, …. And deep!
Chief Executive Officer …
4/21 National Armed Forces Urine Analysis Day!
Come on Hans, file those Fins today! Tweet don’t make it happen anymore!
FY 2022. Control + F (AMD, Emily Chew,
Both Directors have interest in AMD!
https://www.nei.nih.gov/sites/default/files/2021-06/NEI_FY2022_CJ.pdf
Going to be exciting. New Director for NEI Michael F. Chiang, MD has a current
research priority is to integrate these findings with each other to understand better the disease mechanisms and clinical applications of AMD.
Page NEI-16 has task organization chart and highlights Director Chiang's Division leader is Dr. Emily Chew (Partnering with Curative Biotechnology and Dr. Sohn).
What do you hope to achieve here for MEDH?
Simple question. Do you own one single share of MEDH?
This would make an excellent script for a movie. Love the white collar/greed/crime genre.
It’s a dice game here on the OTC weed stocks
Dump or not to Dump?
Hmmm…. Or Double Down? Lol
Lol thanks man. I will.
Hey, at least with marijuana getting federal attention April is looking to be a fun month to watch. 4/20 right around the corner.
Lol we either Rocket or get that tax loss Pocket… either way we win ???? Lol
https://www.otcmarkets.com/stock/MEDH/disclosure
Wow! The previous filings updated. Now 59 filings….
What’s coming????
https://www.otcmarkets.com/stock/MEDH/disclosure
Wow! The previous filings updated. Now 59 filings….
What’s coming????
New World Order for sure is how this all ends, lol
Agree.